BIOMAT Database Logo BIOMAT Database Logo

[Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism]. 1984

E Z Neĭmark, and S K Evtushenko, and M A Dukhovnaia

Based on the established electrophoretic mobility of L-DOPA and on pathogenetic assumptions, the authors carried out multiple modality treatment employing transcerebral L-DOPA electrophoresis in 48 patients with postencephalic and atherosclerotic parkinsonism. The majority of patients (43 subjects) showed an improvement of various degrees, particularly when rigidity and oligo- and bradykinesia were predominant in the clinical picture of the disease. Of the 48 patients treated, 29 received L-DOPA per os and 19 patients were given low drug doses. The therapeutic effect persisted from 2 weeks to 2-3 months.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010301 Parkinson Disease, Postencephalitic Parkinsonism following encephalitis, historically seen as a sequella of encephalitis lethargica (Von Economo Encephalitis). The early age of onset, the rapid progression of symptoms followed by stabilization, and the presence of a variety of other neurological disorders (e.g., sociopathic behavior; TICS; MUSCLE SPASMS; oculogyric crises; hyperphagia; and bizarre movements) distinguish this condition from primary PARKINSON DISEASE. Pathologic features include neuronal loss and gliosis concentrated in the MESENCEPHALON; SUBTHALAMUS; and HYPOTHALAMUS. (From Adams et al., Principles of Neurology, 6th ed, p754) Encephalitis Lethargica Type Parkinsonism,Parkinsonism, Viral Meningoencephalitic,Postencephalitic Parkinsonism,Parkinson Disease, Post-Encephalitic,Parkinsonian Syndrome, Postencephalitis,Parkinsonism, Postencephalitic,Post-Encephalitic Parkinson Disease,Postencephalitic Economo-Type Parkinsonism,Postencephalitic Parkinson Disease,Viral Meningoencephalitic Parkinsonism,von Economo Encephalitis Type Parkinsonism,Economo-Type Parkinsonism, Postencephalitic,Meningoencephalitic Parkinsonism, Viral,Parkinson Disease, Post Encephalitic,Parkinsonism, Postencephalitic Economo-Type,Parkinsonisms, Viral Meningoencephalitic,Post Encephalitic Parkinson Disease,Postencephalitic Economo Type Parkinsonism,Postencephalitis Parkinsonian Syndrome
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D002537 Intracranial Arteriosclerosis Vascular diseases characterized by thickening and hardening of the walls of ARTERIES inside the SKULL. There are three subtypes: (1) atherosclerosis with fatty deposits in the ARTERIAL INTIMA; (2) Monckeberg's sclerosis with calcium deposits in the media and (3) arteriolosclerosis involving the small caliber arteries. Clinical signs include HEADACHE; CONFUSION; transient blindness (AMAUROSIS FUGAX); speech impairment; and HEMIPARESIS. Cerebral Arteriosclerosis,Intracranial Atherosclerosis,Cerebral Atherosclerosis,Arterioscleroses, Cerebral,Arterioscleroses, Intracranial,Arteriosclerosis, Cerebral,Arteriosclerosis, Intracranial,Atheroscleroses, Cerebral,Atheroscleroses, Intracranial,Atherosclerosis, Cerebral,Atherosclerosis, Intracranial,Cerebral Arterioscleroses,Cerebral Atheroscleroses,Intracranial Arterioscleroses,Intracranial Atheroscleroses
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004586 Electrophoresis An electrochemical process in which macromolecules or colloidal particles with a net electric charge migrate in a solution under the influence of an electric current. Electrophoreses
D005260 Female Females

Related Publications

E Z Neĭmark, and S K Evtushenko, and M A Dukhovnaia
[L-Dopa treatment of parkinsonism].
November 1969, Praxis,
E Z Neĭmark, and S K Evtushenko, and M A Dukhovnaia
[L-dopa treatment of parkinsonism].
January 1973, Neurologia i neurochirurgia polska,
E Z Neĭmark, and S K Evtushenko, and M A Dukhovnaia
L-dopa in the treatment of parkinsonism.
January 1972, Gerontologia clinica,
E Z Neĭmark, and S K Evtushenko, and M A Dukhovnaia
[L-dopa in the treatment of Parkinsonism].
August 1972, Wiadomosci lekarskie (Warsaw, Poland : 1960),
E Z Neĭmark, and S K Evtushenko, and M A Dukhovnaia
[L-dopa in the treatment of parkinsonism].
September 1971, Przeglad lekarski,
E Z Neĭmark, and S K Evtushenko, and M A Dukhovnaia
L-Dopa in the treatment of parkinsonism.
January 1970, Clinical pharmacology and therapeutics,
E Z Neĭmark, and S K Evtushenko, and M A Dukhovnaia
L-dopa in the treatment of Parkinsonism.
January 1972, Activitas nervosa superior,
E Z Neĭmark, and S K Evtushenko, and M A Dukhovnaia
[Treatment of parkinsonism with L-dopa].
January 1971, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
E Z Neĭmark, and S K Evtushenko, and M A Dukhovnaia
[Treatment of parkinsonism with L-dopa].
July 1971, L' Infirmiere canadienne,
E Z Neĭmark, and S K Evtushenko, and M A Dukhovnaia
[Treatment of parkinsonism with L-dopa].
January 1970, Acta neurologica latinoamericana,
Copied contents to your clipboard!